HGH Fragment 176-191 (5mg / 10mg)

4.9 stars

$36.00$45.00

5mg
10mg

Earn up to 45 Points.

SKU: N/A Category:

Size Options: 10mg /5mg Composition: Fragment 176-191 Form: Lyophilized Powder Purity: >99% Product Code: P-FRAG176-191

Enjoy Complimentary Shipping on Orders Over $200

Receive a Free 30ml Bac Water with Orders Over $200

Discounts Available for Larger Quantities

Description

HGH Fragment 176-191 (5mg / 10mg)

Fragment 176-191, also referred to as HGH Fragment 176-191 or modified AOD-9604, has garnered attention from researchers due to its potential role in promoting weight loss and fat burning in the body. Additionally, laboratory studies have suggested that it may contribute to elevated IGF-1 levels in experimental subjects. Growth Hormone (HGH), as its name suggests, plays a pivotal role in growth and development during one’s formative years. Beyond growth, HGH also regulates various metabolic functions, including the induction of a hyperglycemic state and the maintenance of body weight.

It’s worth noting that HGH deficiency is relatively common, given the multifaceted benefits of this hormone. In response to this deficiency, scientists have developed several synthetic peptides designed to address these shortcomings. These synthetic HGH peptides serve as shorter analogs of the complete 191 amino acid-containing growth hormone. One such synthetic peptide is Fragment 176-191, which has been a subject of extensive research, primarily focusing on its potential in the realm of weight management.

Overview

Fragment 176-191 is a synthetic peptide comprised of amino acids 176-191, strategically designed to mimic the functions of Growth Hormone (HGH). This synthetic peptide, Fragment 176-191, operates through a mechanism akin to that of HGH, potentially yielding similar effects.

Fragment 176-191, often abbreviated as Frag 176-191, was engineered to emulate HGH, with the capacity to stimulate the anterior pituitary gland. This stimulation has the potential to accelerate metabolic rates and initiate actions reminiscent of HGH, which may foster enhanced growth and development. Furthermore, the recombinant growth hormone, Somatotropin, was created to bind to growth hormone receptors situated in various tissues, primarily in the liver. Once rhGH binds with these receptors, it triggers the production of insulin-like growth factors, namely IGF-1 and IGF-2.

The heightened levels of IGF factors induced by Fragment 176-191 may facilitate glucose regulation and the heightened metabolism of carbohydrates and lipids, contributing to its potential benefits.

Differences Between HGH Fragment 176-191 and HGH

While HGH 176-191 is derived from the C-terminal sequence of human growth hormone (HGH), there are notable distinctions between the unmodified HGH and its fragment. Unlike HGH, HGH 176-191 does not induce diabetes nor elevate IGF-1 levels, which, when excessively high, can lead to gigantism in children or acromegaly in adults. Additionally, HGH 176-191 does not impact carbohydrate metabolism in the body, unlike regular HGH.

Research on HGH Fragment 176-191

Numerous animal and cell-based studies have explored the properties of HGH Fragment 176-191, revealing its potential lipolytic effects, inhibitory action on lipogenesis, and enhanced cytotoxicity against breast cancer cells when combined with specific compounds.

HGH Fragment 176-191 and Fat Loss

Studies have demonstrated that a 14-day administration of HGH Fragment 176-191 resulted in reduced body weight and body fat in obese mice. Researchers attributed this fat loss to increased energy expenditure and fat oxidation. Furthermore, daily treatment with this synthetic peptide increased lipolytic activity in adipose tissues without adversely affecting insulin sensitivity.

HGH Fragment 176-191 and Obesity

Animal studies have indicated that daily treatment with HGH Fragment 176-191 significantly reduced body weight gain, making it a potential therapeutic agent for obesity. Unlike HGH, this fragment did not induce hyperglycemia, reduce insulin secretion, or compete for HGH receptors.

HGH Fragment 176-191 and Breast Cancer

Cell-based research has shown that HGH Fragment 176-191 can enhance the toxicity of compounds targeting breast cancer cells. When loaded into chitosan nanoparticles, it displayed improved cytotoxic efficacy against breast cancer cells, potentially enhancing therapeutic efficiency while minimizing adverse effects on non-target tissues.

HGH Fragment 176-191 and Osteoarthritis

In a 2016 study, HGH Fragment 176-191 loaded into hyaluronic acid demonstrated effectiveness in a rabbit osteoarthritis model, surpassing the outcomes of hyaluronic acid or the HGH fragment administered separately. It was observed that intra-articular administration of HGH Fragment 176-191 promoted cartilage regeneration and reduced morphological and histopathological damage in osteoarthritic rabbits compared to the control group.

CAS Number
PubChem CID
Molecular Weight
Molecular Formula
Synonyms
Storage (Lyophilized) At 39 Fahrenheit: 2 years At -4 Fahrenheit: 3 years

HGH Fragment 176-191 (5mg / 10mg)

Fragment 176-191, also referred to as HGH Fragment 176-191 or modified AOD-9604, has garnered attention from researchers due to its potential role in promoting weight loss and fat burning in the body. Additionally, laboratory studies have suggested that it may contribute to elevated IGF-1 levels in experimental subjects. Growth Hormone (HGH), as its name suggests, plays a pivotal role in growth and development during one’s formative years. Beyond growth, HGH also regulates various metabolic functions, including the induction of a hyperglycemic state and the maintenance of body weight.

It’s worth noting that HGH deficiency is relatively common, given the multifaceted benefits of this hormone. In response to this deficiency, scientists have developed several synthetic peptides designed to address these shortcomings. These synthetic HGH peptides serve as shorter analogs of the complete 191 amino acid-containing growth hormone. One such synthetic peptide is Fragment 176-191, which has been a subject of extensive research, primarily focusing on its potential in the realm of weight management.

Overview

Fragment 176-191 is a synthetic peptide comprised of amino acids 176-191, strategically designed to mimic the functions of Growth Hormone (HGH). This synthetic peptide, Fragment 176-191, operates through a mechanism akin to that of HGH, potentially yielding similar effects.

Fragment 176-191, often abbreviated as Frag 176-191, was engineered to emulate HGH, with the capacity to stimulate the anterior pituitary gland. This stimulation has the potential to accelerate metabolic rates and initiate actions reminiscent of HGH, which may foster enhanced growth and development. Furthermore, the recombinant growth hormone, Somatotropin, was created to bind to growth hormone receptors situated in various tissues, primarily in the liver. Once rhGH binds with these receptors, it triggers the production of insulin-like growth factors, namely IGF-1 and IGF-2.

The heightened levels of IGF factors induced by Fragment 176-191 may facilitate glucose regulation and the heightened metabolism of carbohydrates and lipids, contributing to its potential benefits.

Differences Between HGH Fragment 176-191 and HGH

While HGH 176-191 is derived from the C-terminal sequence of human growth hormone (HGH), there are notable distinctions between the unmodified HGH and its fragment. Unlike HGH, HGH 176-191 does not induce diabetes nor elevate IGF-1 levels, which, when excessively high, can lead to gigantism in children or acromegaly in adults. Additionally, HGH 176-191 does not impact carbohydrate metabolism in the body, unlike regular HGH.

Research on HGH Fragment 176-191

Numerous animal and cell-based studies have explored the properties of HGH Fragment 176-191, revealing its potential lipolytic effects, inhibitory action on lipogenesis, and enhanced cytotoxicity against breast cancer cells when combined with specific compounds.

HGH Fragment 176-191 and Fat Loss

Studies have demonstrated that a 14-day administration of HGH Fragment 176-191 resulted in reduced body weight and body fat in obese mice. Researchers attributed this fat loss to increased energy expenditure and fat oxidation. Furthermore, daily treatment with this synthetic peptide increased lipolytic activity in adipose tissues without adversely affecting insulin sensitivity.

HGH Fragment 176-191 and Obesity

Animal studies have indicated that daily treatment with HGH Fragment 176-191 significantly reduced body weight gain, making it a potential therapeutic agent for obesity. Unlike HGH, this fragment did not induce hyperglycemia, reduce insulin secretion, or compete for HGH receptors.

HGH Fragment 176-191 and Breast Cancer

Cell-based research has shown that HGH Fragment 176-191 can enhance the toxicity of compounds targeting breast cancer cells. When loaded into chitosan nanoparticles, it displayed improved cytotoxic efficacy against breast cancer cells, potentially enhancing therapeutic efficiency while minimizing adverse effects on non-target tissues.

HGH Fragment 176-191 and Osteoarthritis

In a 2016 study, HGH Fragment 176-191 loaded into hyaluronic acid demonstrated effectiveness in a rabbit osteoarthritis model, surpassing the outcomes of hyaluronic acid or the HGH fragment administered separately. It was observed that intra-articular administration of HGH Fragment 176-191 promoted cartilage regeneration and reduced morphological and histopathological damage in osteoarthritic rabbits compared to the control group.

CAS Number 
PubChem CID 
Molecular Weight 
Molecular Formula 
Synonyms 
Storage (Lyophilized)

At 39 Fahrenheit: 2 years

At -4 Fahrenheit: 3 years

Additional information
Size

5mg, 10mg

Related products